Inhibition of CARM1 suppresses proliferation of multiple myeloma cells through activation of p53 signaling pathway

BackgroundMultiple myeloma (MM) is a malignant proliferative disease of plasma cells, the incidence of which is increasing every year and remains incurable. The enzyme co-activator-associated arginine methyltransferase 1 (CARM1) is highly expressed in a variety of cancers, such as Hodgkin's lymphoma and acute myeloid leukemia, and CARM1 is closely associated with tumor cell proliferation. However, the role of CARM1 in MM has not been elucidated.Methods and resultsIn this study, we found that CARM1 is overexpressed in MM and closely associated with poor prognosis in MM. CCK-8 and colony formation assays showed that the proliferation of MM cell lines was downregulated when CARM1 expression was knockdown by specific shRNA. Knockdown of CARM1 reduced the proportion of MM cell lines in the S phase and increased the proportion in G0/G1 phase. RNA-seq analysis of the CARM1-KD cell line revealed that it was closely associated with apoptosis and activated the p53 pathway. CCK-8 and apoptosis results showed that CARM1 knockdown made MM cells more sensitive to standard-of-care drugs.ConclusionThis study provides an experimental basis for elucidating the pathogenesis of multiple myeloma and searching for potential therapeutic targets.

Automated summary

This study found that CARM1 is overexpressed in multiple myeloma (MM) and closely associated with poor prognosis. Knockdown of CARM1 inhibited the proliferation of MM cell lines and altered the cell cycle. RNA-seq analysis revealed the association of CARM1 with apoptosis and the p53 pathway. Knockdown of CARM1 also increased the sensitivity of MM cells to standard-of-care drugs.